Turan, NedimBenekli, MustafaUnal, Olcun UmitUnek, Ilkay TugbaTastekin, DidemDane, FaysalBuyukberber, Suleyman2025-05-102025-05-1020151000-96041993-063110.3978/j.issn.1000-9604.2015.08.032-s2.0-84940553386https://doi.org/10.3978/j.issn.1000-9604.2015.08.03https://hdl.handle.net/20.500.14720/7702Aksoy, Asude/0000-0002-5609-9658; Demirci, Umut/0000-0002-4833-6721; Oven, Bala Basak/0000-0002-9921-4089; Balakan, Ozan/0000-0002-4926-5785; Benekli, Mustafa/0000-0003-3184-4946Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013. Results: Of 563 patients, 472 received adjuvant chemotherapy (CT) alone, chemoradiotherapy (CRT) alone, and chemoradiotherapy plus chemotherapy (CRT-CT) were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival (RFS) and overall survival (OS) were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant difference between groups when patients with node-negative disease or patients with or without positive surgical margins were considered. Conclusions: Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection.eninfo:eu-repo/semantics/closedAccessPancreatic AdenocarcinomaAdjuvant Chemotherapy (Adjuvant Ct)Adjuvant RadiotherapyArticle274Q2N/A40841626361410WOS:000360940900010